Andecaliximab
Product Specifications
UNSPSC Description
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF)[1][2].
Target Antigen
MMP
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/andecaliximab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Andecaliximab]
References & Citations
[1]Andrew E. Greenstein, et al. Effect of andecaliximab (anti-MMP9) on proteolysis of IL-7 in vitro, TCR diversity in mice, and serum IL-7 in gastric cancer patients in combination with chemotherapy. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.|[2]Espindola MS, et al. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Feb 15;203(4):458-470.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99351/Andecaliximab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99351/Andecaliximab-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
1518996-49-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
